Day Mark J.
Known title: EVP, Research & DevelopmentCIK: 0001769845
Associated companies
Transaction History
| IRTC | ▼ Sell | Open Market | 3,248 | $361K | 3/4/2024 | View on chart |
| IRTC | ▼ Sell | Open Market | 1,475 | $180K | 2/29/2024 | View on chart |
| IRTC | ▲ Buy | Grant | 7,734 | $0 | 2/28/2024 | View on chart |
| IRTC | ▲ Buy | Grant | 2,621 | $0 | 2/27/2024 | View on chart |
| IRTC | ▲ Buy | Option Exercise | 486 | $18K | 8/3/2023 | View on chart |
| IRTC | ▼ Sell | Open Market | 2,116 | $248K | 3/3/2023 | View on chart |
| IRTC | ▼ Sell | Open Market | 1,898 | $224K | 2/28/2023 | View on chart |
| IRTC | ▼ Sell | Open Market | 15 | $2K | 2/28/2023 | View on chart |
| IRTC | ▲ Buy | Grant | 8,354 | $0 | 2/27/2023 | View on chart |
| IRTC | ▲ Buy | Grant | 3,468 | $0 | 2/27/2023 | View on chart |
| IRTC | ▼ Sell | Open Market | 2,518 | $334K | 3/4/2022 | View on chart |
| IRTC | ▼ Sell | Open Market | 3,975 | $481K | 2/17/2022 | View on chart |
| IRTC | ▼ Sell | Open Market | 87 | $10K | 2/17/2022 | View on chart |
| IRTC | ▲ Buy | Grant | 7,152 | $0 | 2/15/2022 | View on chart |
| IRTC | ▲ Buy | Grant | 6,018 | $0 | 2/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
iRhythm Reports Data Breach and Completes VitalConnect Acquisition
iRhythm disclosed unauthorized access to patient data, a significant security event for a healthcare company. The firm also completed the acquisition of VitalConnect to expand its cardiac monitoring platform across various care settings. Analyst views remain mixed, with Wells Fargo lowering its price target to $150 while Needham raised its target to $194.
iRhythm Reports Data Breach and Completes VitalConnect Acquisition. iRhythm disclosed unauthorized access to patient data, a significant security event for a healthcare company. The firm also completed the acquisition of VitalConnect to expand its cardiac monitoring platform across various care settings. Analyst views remain mixed, with Wells Fargo lowering its price target to $150 while Needham raised its target to $194.